FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 17, 2026
Eloxx Pharmaceuticals, Inc. (ELOX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $6.0 million. As of Jun 30, 2026 it held $62.0 million in cash and investments and $0 in total debt.
Revenue
$0
Net income
$-6.00M
+83.4% vs prior year
Operating cash flow
$-6.33M
+80.1% vs prior year
Free cash flow
$-31.91M
+9.1% vs prior year
EPS
$-0.49
+97.1% vs prior year
Dividend per share
None
Shares outstanding
5.07M
+134.1% vs prior year
Net cash
$61.96M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ELOX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1035354
- Former names
- Sevion Therapeutics, Inc. (until Dec 22, 2017); SENESCO TECHNOLOGIES INC (until Sep 29, 2014); NAVA LEISURE USA INC (until May 24, 1999)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — |
| Operating income | -$6.4M | -$34.4M | -$66.0M | -$33.5M | -$50.6M |
| Net income | -$6.0M | -$36.1M | -$66.7M | -$34.6M | -$50.9M |
| Diluted EPS | -$0.49 | -$16.65 | — | — | — |
| Operating cash flow | -$6.3M | -$31.8M | -$35.0M | -$28.2M | -$39.4M |
| Free cash flow | — | -$31.9M | -$35.1M | — | -$39.4M |
| Total assets | $5.3M | $21.1M | $45.1M | $26.5M | $58.9M |
| Total liabilities | $17.2M | $31.8M | $22.8M | $16.2M | $22.7M |
| Stockholders' equity | -$11.9M | -$10.7M | $22.4M | $10.2M | $36.2M |
| Cash and investments | $4.8M | $19.2M | $42.3M | $24.7M | $56.3M |
| Total debt | $1.0M | $13.4M | $13.5M | $12.0M | $15.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Oct 22, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change
|
Jun 1, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 1, 2026 | Apr 28, 2026 |
All 1000 Eloxx Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.